Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioVersys
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
May 22, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
May 22, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
May 21, 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
May 17, 2026
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
May 17, 2026
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
May 16, 2026
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
March 31, 2026